Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018

Long-awaited results proving two classes of cardiovascular disease drugs can reduce the risk of heart attack and stroke in 2018 could cause sales to soar for Amgen (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), and Amarin Corp (NASDAQ: AMRN).

In this clip from The Motley Fool’s Industry Focus: Healthcare, analyst Shannon Jones is joined by Todd Campbell to discuss how investors were rewarded in 2018.

Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:

Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter:


1 Comment
  1. Class Act says

    Well that good because a lot of people are going to need those drugs when the World Economy Crashes in 2019.

Leave a Reply

%d bloggers like this: